Company
Headquarters: Nedlands, WA, Australia
A$66.0 Million
AUD as of Jan. 1, 2024
US$44.9 Million
Company | Market Cap (USD) |
---|---|
Abbott | $192.67 B |
Stryker Corporation | $113.24 B |
Medtronic | $111.60 B |
Boston Scientific Corporation | $85.22 B |
Shenzhen Mindray Bio-Medical Electronics Co. Ltd | $49.33 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
Neurotech International Limited, together with its subsidiaries, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company is focused on developing neurostimulation and neurodiagnostic solutions to be delivered through the Mente platform, a platform technology to enable medical practitioners to remotely monitor and play role in home-based therapies. Its product includes Mente Autism for the diagnosis and treatment of autism. It also engages in executing of medical research projects; and developing of technological devices. The company was incorporated in 2016 and is based in Nedlands, Australia.
Top 1-year algo backtest: +284.14%
$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Neurotech International Limited has the following listings and related stock indices.
Stock: ASX: NTI wb_incandescent